• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Biohaven's genetic disease drug meets main trial goal

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 23, 2024 at 10:02: AM
via Biohaven (BHVN.N) has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.
The drug troriluzole showed clinically meaningful slowing of disease progression in patients with Spinocerebellar Ataxia (SCA), the company said.

article source
 




Top Bottom
Back
Quote